HC Wainwright reissued their buy rating on shares of Voyager Therapeutics (NASDAQ:VYGR – Free Report) in a report released on ...

Cantor Fitzgerald reaffirmed their overweight rating on shares of Voyager Therapeutics (NASDAQ:VYGR – Free Report) in a ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Voyager Therapeutics (VYGR – Research Report), ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Teleflex (TFX – Research Report) and Voyager Therapeutics ...

Voyager Therapeutics (VYGR) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to earnings of $1.25 per share a year ago.

Q4 2024 Earnings Call Transcript March 11, 2025 Voyager Therapeutics, Inc. misses on earnings expectations. Reported EPS is $ ...

Good afternoon, and welcome to Voyager Therapeutics Fourth Quarter and Year-End 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. There will be a ...

Analysts have set 12-month price targets for Voyager Therapeutics, revealing an average target of $18.93, a high estimate of ...

The gene therapy company posted revenue of $6.3 million in the period, which also missed Street forecasts. Five analysts surveyed by Zacks expected $20.1 million. For the year, the company reported a ...